Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants

•Combined vaccine formulations PHiD-CV with 10 or 30µg of dPly and PhtD were assessed.•They were co-administered with DTPa-HBV-IPV/Hib in infants (3+1 schedule)•No increase of fever (>40°C) post-doses 1–3 was demonstrated compared to PHiD-CV.•No safety concerns were raised.•dPly/PhtD were immunogenic; post-dose 3 the 30µg formulation was superior to 10µg.•Immunogenicity of conjugates and co-administered antigens did not seem altered.